Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 18/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045129 | 1.00 | DGAT2 (0.53) | DGAT2PIK3CDABL1EGFRHCK | |
| SCHEMBL24045196 | 0.87 | DGAT2 (0.47) | DGAT2 | |
| SCHEMBL30314620 | 0.87 | DGAT2 (0.47) | DGAT2 | |
| SCHEMBL30314866 | 0.87 | DGAT2 (0.43) | DGAT2KMT2A | |
| SCHEMBL24045010 | 0.87 | DGAT2 (0.43) | DGAT2KMT2A | |
| SCHEMBL24045084 | 0.86 | KMT2A (0.44) | DGAT2KMT2A | |
| SCHEMBL30314710 | 0.86 | KMT2A (0.44) | DGAT2KMT2A | |
| SCHEMBL24045176 | 0.85 | DGAT2 (0.41) | DGAT2KMT2A | |
| SCHEMBL24045288 | 0.85 | DGAT2 (0.53) | DGAT2 | |
| SCHEMBL24045117 | 0.85 | DGAT2 (0.42) | DGAT2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448384-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240059700-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-02-22 | — | — | US | disclosed |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4153584-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059700-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | DGAT2 1/4885PIK3CD 1315/4885ABL1 3766/4885 |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | DGAT2 1/4885PIK3CD 1430/4885ABL1 3303/4885 |
| US-12448384-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | DGAT2 1/4885PIK3CD 1430/4885ABL1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.